RLYB Rallybio Corp: Rasio nilai perusahaan marang pendapatan

Rallybio Corporation develops biologics for ultra-rare diseases, securing monopoly profits through patent protection. The EV/Sales history reflects the market consensus on business valuation relative to revenue. The -16581.40 mark captures this metric, while the clinical trial outsourcing model and the development of antibodies for preventive medicine maintain team flexibility without capital expenditures.
Rallybio Corp - rincian analitis lan metrik utama (RLYB)

This ratio determines the market value of the business minus net debt relative to sales volume, measuring the density of investment expectations and excluding the impact of leverage. By analyzing the current enterprise value-to-revenue level, an investor assesses the capitalization efficiency of Rallybio Corporation (RLYB), where valuation stability depends directly on the reliability of premium biocomponent logistics and the absence of drug supply disruptions.